





## Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey

Manuela Funke-Chambour <sup>1</sup>, Carlo Albera<sup>2</sup>, Elisabeth Bendstrup <sup>3</sup>, Ulrich Costabel <sup>4</sup>, Jan C. Grutters<sup>5</sup>, Sergio Harari <sup>6</sup>, Kerri A. Johannson <sup>7</sup>, Michael Kreuter <sup>8</sup>, Irina Strambu<sup>9</sup>, Carlo Vancheri <sup>10</sup>, Francesco Varone <sup>11</sup>, Patrizio Vitulo <sup>12</sup>, Wim A. Wuyts <sup>13</sup>, Fernando Martinez <sup>14,16</sup> and Ganesh Raghu <sup>15,16</sup>, on behalf of Erice participants

Affiliations: <sup>1</sup>Dept of Pulmonary Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. <sup>2</sup>Dipartimento di Scienze Mediche, Università di Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza – Molinette, Turin, Italy. <sup>3</sup>Dept of Respiratory Diseases and Allergology, Aarhus University Hospital, Aarhus, Denmark. <sup>4</sup>Center for Interstitial and Rare Lung Diseases, Ruhrlandklinik, University Hospital Essen, Essen, Germany. <sup>5</sup>ILD Center of Excellence, St. Antonius Hospital, Nieuwegein, The Netherlands. <sup>6</sup>University of Milan, Dept of Medicine, Division of Internal Medicine, Division of Pulmonary Disease, Ospedale San Giuseppe MultiMedica IRCCS, Milan, Italy. <sup>7</sup>University of Calgary, South Health Campus, Calgary, AB, Canada. <sup>8</sup>Center for Interstitial and Rare Lung Diseases, Thoraxklinik – University Hospital Heidelberg, German Center for Lung Research, Heidelberg, Germany. <sup>9</sup>University of Medicine and Pharmacy "Carol Davila", Bucharest, Romania. <sup>10</sup>AOU "Policlinico Vittorio Emanuele", Catania, Italy. <sup>11</sup>Fondazione Policlinico A. Gemelli IRCCS, Rome, Italy. <sup>12</sup>IRCCS ISMETT, Palermo, Italy. <sup>13</sup>Unit for Interstitial Lung Diseases, Dept of Respiratory Medicine, University Hospitals Leuven, Belgium. <sup>14</sup>Weill Cornell Medicine Pulmonary and Critical Care Medicine, New York, NY, USA. <sup>15</sup>Center for Interstitial Lung diseases, Depts of Medicine; Laboratory Medicine and Pathology (adjunct), University of Washington, Seattle, WA, USA. <sup>16</sup>Cosenior authors

Correspondence: Manuela Funke-Chambour, Inselspital, Pulmonology, Bern University Hospital, University of Bern, Bern 3010, Switzerland. E-mail: manuela.funke-chambour@insel.ch

## @ERSpublications

Evidence-based guideline development is challenging. Implementation can be suboptimal. A Delphi survey among clinical experts evaluated possibilities to improve clinical utility and implementation of IPF and other ILD guidelines. http://bit.ly/3avcOug

**Cite this article as:** Funke-Chambour M, Albera C, Bendstrup E, *et al.* Suggestions for improving clinical utility of future guidelines for diagnosis and management of idiopathic pulmonary fibrosis: results of a Delphi survey. *Eur Respir J* 2021; 57: 2004219 [https://doi.org/10.1183/13993003.04219-2020].

This single-page version can be shared freely online.

## To the Editor:

Medical guidelines on diagnosis and management of relevant diseases aim to make recommendations for clinical practice while standardising patient care. However, evidence-based guideline development is laborious and challenging, the recommendations require nuanced wording, and the optimal approach remains controversial.

Copyright ©ERS 2021